Xbrane Biopharma
6.01 SEK
-1.30 %
Less than 1K followers
XBRANE
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Xbrane Biopharma
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 57.6 | 238.7 | 198.7 | 152.4 | |||
| growth-% | 314.3 % | -16.8 % | -23.3 % | ||||
| EBITDA | -140.5 | -218.7 | -168.4 | -149.6 | -288.4 | -127.7 | -13.6 |
| EBIT | -164.6 | -225.3 | -180.6 | -166.2 | -322.2 | -217.9 | -28.2 |
| Profit before taxes | -166.0 | -226.0 | -183.2 | -168.5 | -322.0 | -253.4 | -43.9 |
| Net income | -166.0 | -226.0 | -188.4 | -172.5 | -388.2 | -266.2 | 127.2 |
| EPS | -210.27 | -176.83 | -110.11 | -95.65 | -191.59 | -27.50 | 0.08 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | 0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -259.7 % | -120.8 % | -64.3 % | -9.0 % | |||
| EBIT-% | -288.5 % | -134.9 % | -109.7 % | -18.5 % | |||
| ROE | -90.1 % | -87.7 % | -43.6 % | -40.6 % | -226.5 % | -127.7 % | 22.7 % |
| ROI | -49.0 % | -48.7 % | -27.4 % | -25.0 % | -59.4 % | -31.6 % | 18.9 % |